UNSPSC 51294200: Antidepressant oxazines

Antidepressant drugs made from six-membered heterocycles containing an oxygen and a nitrogen.

UNSPSC 51294200 Antidepressant oxazines is a Class code that shows significant mismatch between its nominal scope and actual state and local buying activity. Recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution—none of which align with antidepressant oxazines specifically. The code's recent activity spans pharmaceutical procurement across counties, state health agencies, and multistate cooperative purchasing vehicles, but the sourcing reflects broader pharmacy benefit management and emergency response pharmaceutical supply rather than the targeted therapeutic class the code nominally describes. Issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating states including Oregon).

Recent solicitation activity concentrates in Florida and Texas, with multistate cooperative purchasing extending to Oregon and other MMCAP member jurisdictions. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source); the contract carries a two-year initial term with optional one-year renewal and requires quarterly deliveries. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesaler channels, signaling early-stage market research before formal RFP issuance. Minnesota's MMCAP issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and establish pricing effective July 1, 2026. The code shows little relevant recent activity aligned to its stated scope.